NLS Pharmaceutics Shareholders Approve Most Proposals
Ticker: NCEL · Form: 6-K · Filed: Jan 7, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jan 7, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
TL;DR
NLS Pharma shareholders OK'd everything except one item that wasn't even voted on. Meeting Jan 7.
AI Summary
On January 7, 2025, NLS Pharmaceutics Ltd. held an extraordinary shareholders' meeting where all proposed agenda items were approved, except for Proposal 6, which was not put to a vote. The company is incorporated in Switzerland and its principal executive offices are located in Zurich.
Why It Matters
Shareholder approval of agenda items is crucial for a company's governance and strategic direction, indicating alignment between management and investors on key decisions.
Risk Assessment
Risk Level: low — This filing is a routine report of shareholder meeting results and does not contain significant new financial or operational information that would inherently increase risk.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- January 7, 2025 (date) — Date of shareholders' meeting
- Proposal 6 (agenda_item) — Item not voted on
FAQ
What was the outcome of the extraordinary shareholders' meeting for NLS Pharmaceutics Ltd. on January 7, 2025?
All agenda items were approved by shareholders, except for Proposal 6, which was not put to a vote.
Which specific proposal was not approved or voted on at the NLS Pharmaceutics meeting?
Proposal 6 was not approved because it was not put to a vote at the Meeting.
What is the filing date for this Report of Foreign Private Issuer?
The filing date is January 7, 2025.
Where are the principal executive offices of NLS Pharmaceutics Ltd. located?
The principal executive offices are located at The Circle 6, 8058 Zurich, Switzerland.
Does NLS Pharmaceutics Ltd. file annual reports under Form 20-F or Form 40-F?
NLS Pharmaceutics Ltd. files annual reports under cover of Form 20-F.
Filing Stats: 263 words · 1 min read · ~1 pages · Grade level 12.6 · Accepted 2025-01-07 16:30:13
Filing Documents
- ea0227024-6k_nlspharma.htm (6-K) — 10KB
- 0001213900-25-001667.txt ( ) — 11KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: January 7, 2025 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2